Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“ctDNA offers a real-time window into lymphoma treatment response
In a prospective study of newly diagnosed large B-cell lymphoma (LBCL):
- ctDNA was detectable in 79% of patients at baseline and strongly correlated with total metabolic tumor volume (TMTV) (ρ = 0.90; P < .0001).
- ctDNA kinetics mirrored PET-CT changes and identified relapsing or refractory disease earlier.
- TMTV was quantified using AI-based PET analysis (RECOMIA), highlighting the synergy between molecular and imaging biomarkers.
- ctDNA-based MRD monitoring offers a sensitive, complementary approach to PET-CT—enhancing early detection of treatment response and relapse in LBCL.”
Title: Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics
Authors: Gayaththri Vimalathas, Marcus Høy Hansen, Oriane Cédile, Mads Thomassen, Michael Boe Møller, Sara Kamuk Dahlmann, Marie Louise Grube Kjeldsen, Malene Grubbe Hildebrandt, Anne Lerberg Nielsen, Mohammad Naghavi-Behzad, Lars Edenbrandt, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen
Read the full article on Blood Advances.
More posts featuring Yan Leyfman on OncoDaily.